Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Caitlin N Daniels und 5 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Discovery, Development and Diagnostics, Countermeasures Development, Evaluation and Preparedness Division, UK Health Security Agency, P…. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents, Electric Impedance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: UKHSA Placement Studentship, UKHSA, National Institute for Health and Care Research.
Abstract (Originalsprache)
Objectives
Antimicrobial-resistant Neisseria gonorrhoeae is a serious threat to global health. Current N. gonorrhoeae antimicrobial susceptibility testing (AST) is laborious and time consuming (≥2 days) leading to overprescription of last-resort, broad-spectrum antibiotics. In this proof-of-principle study, we developed a fast (<8 h) phenotypic, impedance-based AST for N. gonorrhoeae against frontline and experimental antibiotics.
Methods
WHO N. gonorrhoeae reference strains F, K, O, V, X and Y were exposed to EUCAST susceptibility breakpoint concentrations of ceftriaxone, ciprofloxacin and azithromycin for up to 5 h and to doubling dilutions of antibiotics for 4 h. The % cell count of antibiotic exposed compared with unexposed control samples, as measured by an impedance-based Fast Antimicrobial Susceptibility Test (iFAST®), was used to differentiate between susceptible and non-susceptible strains. Responses to novel antimicrobial compounds, including zoliflodacin and gepotidacin, were also measured by iFAST® and compared with published MICs.
Results
The protocol reported susceptibility profiles concordant with published data for all strain-drug combinations after 4 h of exposure. Dose–response curves generated using iFAST® for most strain-drug combinations were in essential agreement with published Etest MIC values. Novel compounds assessed using iFAST® showed higher antimicrobial activity than ciprofloxacin in the high-level resistant strain WHO X. Conclusions iFAST® AST results were concordant with the current clinical standards and measured in under 8 h. This method is therefore promising for the development of a rapid and accurate phenotypic N. gonorrhoeae antimicrobial susceptibility test.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Antimicrobial Discovery, Development and Diagnostics, Countermeasures Development, Evaluation and Preparedness Division, UK Health Security Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK.
- Department of Natural Sciences, Faculty of Science & Technology, Middlesex University, The Burroughs, Hendon, London NW4 4BT, UK.
- Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK.
ORCID-Profile: Khondaker Miraz Rahman
Förderung
- UKHSA Placement Studentship
- UKHSA
- National Institute for Health and Care Research
- Invention for Innovation (i4i)
- Programme
- UKHSA-
Zitieren
APA
Daniels, C. N., Martin, B. K., Nahar, K. S., Rahman, K. M., Sutton, J. M., & Bock, L. J. (2026). Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf493
Vancouver
Daniels CN, Martin BK, Nahar KS, Rahman KM, Sutton JM, Bock LJ. Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf493
BibTeX
@article{Daniels2026,
author = {Daniels, Caitlin N and Martin, Bethany K and Nahar, Kazi S and Rahman, Khondaker Miraz and Sutton, J Mark and Bock, Lucy J},
title = {Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf493}
}
EUVIMED